In ibrutinib therapy, clinicians usually decide what dose of ibrutinib to use and the treatment cycle based on factors such as the patient's condition and constitution. When using ibrutinib, you should follow the doctor's advice and do not adjust the dose or stop the drug without authorization. At the same time, since ibrutinib may cause certain adverse reactions, such as rash and nausea, please pay close attention to the patient's physical condition, be aware of any abnormal reactions in the patient at any time, and contact the doctor in time for guidance.
Read more- https://www.medixocentre.com/i....brutinib-cost-malays

Enzalutamide (XTANDI) has an unshakable position in the treatment of metastatic prostate cancer, and clinicians treating patients with advanced prostate cancer internationally are also very interested in enzalutamide. Familiar, becoming the standard of care for metastatic castration-resistant prostate cancer. Research shows that early first-line treatment of metastatic prostate cancer has higher antigen response rates, longer survival, and lower risk of fatigue.

https://www.medixocentre.com/enzalutamide-40-mg